SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

See All 47 Photos For the past 60-plus years, the Shelby Cobra has been the shining star of that amalgamation of premium ...

We are nearing the halfway mark of our 10th annual Alcohol Free for 40 Challenge, a time when motivation can waver, and those ...

Priced in the U.K. at 54,995 pounds (roughly $71,300) in base (Trophy) guise, the Cyberster squares off directly against the ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

MG Comet EV and Tata Tiago EV are two entry-level products in the segment from their respective brands and both have been ...

Even 75 years after its manufacturing, MG YT tourer continues to win hearts and charm people, as it picked award at 11th ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

On Monday, 1608 stocks advanced, 2503 declined and 130 remained unchanged on Bombay Stock Exchange with advance decline ratio ...

Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus ...